# Wave32-D / Hour-9 Hostile Critique

Timestamp: 2026-05-27 08:04 UTC

Role: hostile review after Waves 30-32. This report does not claim a finding.

## Verdict

Reject the lipid-lysosomal/IFN-HLA-II module as the active therapeutic-discovery
route under the V3 DoD. Preserve it as a disease-state scaffold, comparator,
and biomarker hypothesis only.

The module has now failed three non-redundant intervention framings:

- Static niche/upstream driver: 18 axes audited, 0 promoted. The most central
  axes were IFNG/IFNGR/JAK/STAT1/CIITA, MIF/CD74, LILRB/HLA, and SPP1/CD44,
  but these are central state drivers rather than selective therapy points.
- Dynamic transition controller: 17 candidates audited, 0 promoted. MED16_KO is
  the best perturbation comparator but MED16 is not druggable, and the
  CDK8/CDK19 translation path lacks an autoimmune APC phenocopy.
- Downstream resolution/rescue: 14 routes audited, 0 promoted. TREM2/APOE is
  parked, not promoted; NPC1/NPC2 and LIPA remain readout or prior-art-blocked
  routes; MERTK/TAM is biologically attractive but modality-immature.

Continuing to mine this module for a target is now more likely to produce proxy
satisficing than discovery.

## Answer 1: Is The Module Exhausted?

Yes, as a therapeutic-discovery route for this session.

Reject criteria now met:

- No node combines cross-disease breadth, target-level causal genetics or real
  perturbation, selective disease-module effect, correct-direction modality,
  acceptable safety, and non-blocking prior art.
- The best central nodes are generic host-defense or antigen-presentation
  machinery.
- The best perturbation result is not a druggable target.
- The best resolution nodes are markers of injured or repairing phagocytes, not
  demonstrated causal levers.

Not exhausted:

- As a biomarker scaffold for lesion/tissue state.
- As a wet-lab comparator panel.
- As a patient-stratification axis if later linked to a therapy response
  dataset.

## Answer 2: Reopening Rules For Resolution Routes

Do not reopen any of these routes on expression, literature plausibility, or
route-level scoring alone.

### TREM2/APOE

Current decision: reject as target claim; park as repair-biology comparator.

Required evidence to reopen:

- Human microglia/macrophage perturbation with TREM2 agonism or pathway
  activation in myelin/lipid-loaded IFN-conditioned cells.
- Effect must show at least 30 percent reduction in damaging inflammatory or
  antigen-presentation output while preserving or increasing debris clearance
  and viability.
- Spatial protein or CITE/spatial transcriptomic evidence in MS lesions showing
  the TREM2/APOE state predicts remyelination or non-expanding lesions
  independent of microglial density, APOE genotype, age, and lesion stage.
- A target-specific genetic, pQTL, or colocalization anchor, not just APOE/TREM2
  expression.
- A novelty delta against neurodegeneration TREM2 agonism prior art.

### MERTK/TAM

Current decision: reject until an agonist modality and disease direction are
real.

Required evidence to reopen:

- Direct MERTK/AXL/TYRO3 agonism or engineered GAS6/PROS1 perturbation in human
  macrophages/microglia, with target engagement.
- Increased efferocytosis/myelin-debris clearance with no broad suppression of
  antimicrobial or antigen-presentation guardrail genes.
- Recurrence in at least three tissues, for example MS lesion microglia, RA
  synovial macrophages, and IBD lamina propria macrophages.
- Clear distinction from oncology TAM-inhibitor pharmacology.
- A feasible agonist delivery format and safety argument.

### LIPA

Current decision: reject as route; prior V3 evidence is marker-skewed and
directionally unsafe.

Required evidence to reopen:

- Myeloid-specific LIPA perturbation, preferably gain-of-function/enhancement,
  showing reversal of lipid-lysosomal inflammatory state rather than generic
  lysosomal stress.
- MS-specific anchor in lesion microglia/macrophages, not epithelial,
  keratinocyte, or ductal stress.
- Quantitative lipid flux readout, not transcript abundance alone.
- Delivery path for CNS or target tissue lysosomal enzyme enhancement.
- Prior-art delta over lysosomal acid lipase and CNS repair claims.

### NPC1/NPC2

Current decision: reject as intervention; keep as cholesterol-egress readout.

Required evidence to reopen:

- A pharmacologic or genetic activation route that increases cholesterol egress
  in disease APCs under autoimmune-relevant stimulation.
- Reduced pathogenic cytokine/APC output with preserved repair and viability.
- MS lesion anchor and replication in at least two non-CNS autoimmune tissues.
- Target engagement biomarker for cholesterol trafficking.
- Delivery feasibility beyond rare-disease lysosomal biology.

## Answer 3: Next Forced Pivot

Pivot outside myeloid lipid/IFN-HLA-II biology to a genetics-first lymphocyte
checkpoint axis:

Candidate forcing question:

Does the CD226/TIGIT/PVR-PVRL2 costimulatory checkpoint define a shared
autoimmune effector-lymphocyte transition across MS, T1D, RA, SLE, celiac
disease, Sjogren's disease, psoriasis, and IBD, and can CD226 blockade or TIGIT
agonism reduce tissue-invasive cytotoxic/helper effector programs without
collapsing antiviral defense or Treg function?

Why this pivot:

- It is outside the failed lipid-resolution module.
- It is genetically plausible across multiple autoimmune diseases.
- It has a tractable modality class, namely antibodies or engineered checkpoint
  agonists/antagonists.
- Oncology has generated relevant chemical/biologic tooling, but autoimmune
  use may have a different direction and safety logic.
- It can be tested with existing GWAS, eQTL/pQTL, single-cell T/NK atlases,
  perturbation data, and foundation-model perturbation predictions.

Accept criteria:

- Target-level colocalization or credible-set/eQTL/pQTL evidence at CD226,
  TIGIT, PVR, or PVRL2 in at least four autoimmune diseases, with pleiotropy
  checks.
- Disease-enriched CD226-high/TIGIT-low or PVR/PVRL2 ligand-exposed effector
  T/NK state in at least three tissues, including one MS-relevant dataset.
- Real perturbation data or foundation-model prediction validated against real
  perturbation showing at least 30 percent reduction in pathogenic effector
  cytokine/cytotoxic modules, with Treg and antiviral guardrails preserved.
- Druggability audit finding a feasible autoimmune-direction modality and no
  blocking patent/trial prior art for the specific cross-autoimmune use.

Reject criteria:

- Genetic signal does not colocalize with target expression/protein.
- Cell-state signal is only blood activation or cell-composition shift.
- Perturbation suppresses all T/NK function nonspecifically.
- Prior art already claims the same autoimmune indication and direction.
- MS evidence is absent or only generic lymphocyte abundance.

## Answer 4: Hidden Failure Modes In Wave32

- Route-level scoring can launder marker coexpression into causality. NPC1/NPC2
  scored highest because they tracked the state, not because egress activation
  was demonstrated.
- "Resolution" is directionally ambiguous. The same genes can mark repair,
  fibrosis, phagocyte burden, apoptotic-cell load, or chronic injury.
- Cross-disease breadth risks counting shared tissue damage rather than shared
  autoimmune mechanism.
- Correct-direction modality was sometimes hypothetical. TAM/MERTK agonism and
  TREM2 agonism cannot be treated as available therapeutic routes without
  disease-relevant perturbation data.
- TREM2/APOE has narrative gravity from MS and neurodegeneration. That is a
  confirmation-bias trap because prior art is crowded and the V3 support is not
  target-causal.
- Literature/API saturation snapshots are not novelty proof. A positive route
  would still require full patent, trial, preprint, and disease-specific prior
  art review.

## Hostile Recommendation

Stop spending active discovery cycles inside the lipid-lysosomal/IFN-HLA-II
module unless a new real perturbation or target-level genetic anchor appears.
The next analysis should test CD226/TIGIT/PVR-PVRL2 as a cross-autoimmune
lymphocyte checkpoint program with hard genetic, cell-state, perturbation,
guardrail, and prior-art gates.
